Login to Your Account

Alvogen eyes large opportunity in Korea in deal for Vivus' Qsymia

By David Ho
Staff Writer

Friday, September 15, 2017

HONG KONG – Alvogen Korea Ltd. has announced an agreement for exclusive rights to license, sell and market Vivus Inc.'s obesity drug, Qsymia, in South Korea, a deal expected to shore up the company's strong position in the Korean market.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription